Skip to main content
. 2018 May 18;9(38):25277–25284. doi: 10.18632/oncotarget.25423

Table 2. Relationships between C0 and adverse events.

Hand foot syndrome Thrombocytopenia Hypertention Hypothiroidism Fatigue
(G0 vs ≥ G1) (G0 vs ≥ G1) (G0 vs ≥ G1) (G0 vs ≥ G1) (G0 vs ≥ G1)
Median p Median p Median p Median p Median p
SU C0 48.3 vs 89.5 <0.01 50.8 vs 89.5 0.02 54.8 vs 65.8 0.90 50.8 vs 71.2 0.08 49.6 vs 70.1 0.06
DSU C0 12.9 vs 15.2 0.88 11.9 vs 16.2 0.44 11.7 vs 15.3 0.82 11.7 vs 16.2 0.55 11.7 vs 15.7 0.64
SU + DSU C0 64.2 vs 75.2 <0.01 64.4 vs 75.2 0.01 67.2 vs 77.5 0.82 64.4 vs 94.1 0.07 64.3 vs 91.5 0.16

Abbreviations: G, grade; SU, sunitinib; C0, predose drug concentration; DSU, N-desetyl sunitinib.